RJ Tesi, M.D., co-founder and CEO of clinical-stage immunology company INmune Bio (NASDAQ: INMB), was recently featured in an interview with multimedia financial reporter Jason Lin. Among other highlights, Dr. Tesi discusses recent company accomplishments in the interview. “Nasdaq’s MarketSite is a premiere platform for INmune Bio to share our story with investors and to discuss recent developments in our programs for cancer, Alzheimer’s disease and nonalcoholic steatohepatitis (NASH) liver disease,” INmune co-founder and CEO Dr. RJ Tesi stated in the interview. “We hope to continue reaching new milestones in the development of therapies that target the innate immune system.” The company also announced today that CJ Barnum, Ph.D., Director of Neuroscience, will be presenting on “Approaching Alzheimer’s disease as an immunological disease: role of biomarkers” at the World Immunotherapy Congress taking place on October 16 in Switzerland.
To view the interview, visit http://nnw.fm/fGd1c
To view the full press release, visit http://nnw.fm/2NBFd
About INmune Bio, Inc.
INmune Bio is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03), Alzheimer’s (XPro595), and NASH (NeuLiv). The Innate Immune Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. For more information, visit the company’s website at www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://nnw.fm/INMB
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]